Panel discussion
Menarini Group
| Website: | www.menarini.com |
| Date: | April 23, 2024 |
| Time: | 15:00-15:45 |
| Room: | Rio |
Panel title
AMR: From Awareness to Action. The time is now to invest.
Panel summary
Building on “Beyond Antibiotics: The Reckoning of Antimicrobial Resistance, A New Biological Frontier”, experts address one of the biggest global challenges of our time. Covering everything from the duality of oncology & infectious diseases, sustainable & scalable manufacturing, attracting & retaining global expertise and rethinking investment & commercial incentives, the session will provide actionable insights into practical steps the industry must take to combat AMR.
Speaker information
Moderation
Guillermo Tramontin, Principal Consultant, Cavenagh Health
Panelists
Najy Alsayed, Global Therapeutic Area Head – Infectious Diseases, Menarini Group
Morgane Vanbiervliet, Market Intelligence & Business Development Manager – Infectious Diseases, Debiopharm International SA
Yann Ferrisse, Director, Business Development & Partner Engagement, Global Antibiotic R&D Partnership (GARDP)
William Burns, Board Chair, AMR Action Fund
Company profiles
The Menarini Pharmaceutical Group, with headquarters in Florence, is present in 140 countries worldwide to date, with €4,375 million in turnover and more than 17,000 employees. With 9 centres for Research & Development, Menarini’s products are present in the most important treatment areas, including those of cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesic products. Pharmaceutical production is carried out in the Group’s 18 manufacturing plants, located in Italy and abroad, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients throughout the world.
Cavenagh Health fosters connections that drive impact, collaborating with over 200 life science investors and industry leaders to accelerate meaningful transformation in the future of healthcare through frontier science and technology.
We are trusted by pioneering therapeutic and health technology organizations worldwide to build high-performing teams that strive to create lasting impact for patients and their families globally.
